U.K. biopharma on the move. Plus: IRA, Biosecure — a BioCentury podcast

The U.K.’s biotech sector is maturing; what’s needed to get to the next level? And the latest on the Inflation Reduction Act and Biosecure Act

The U.K.’s life sciences ecosystem boasts “palpable energy at the very innovation end of the spectrum in biotech, with a lot of really quality science,” BioCentury Editor in Chief Simone Fishburn says on the latest BioCentury This Week podcast. Fishburn assesses the maturation of the country’s biotech industry, including the need for an influx of capital to catalyze the sector’s growth.

Washington Editor Steve Usdin then joins the podcast to discuss the latest developments for the Inflation Reduction and the Biosecure acts as well as the benefits of the breakthrough therapy pathway.

Also on BioCentury.com, listeners may want to check out Danielle Golovin’s analysis of LNP innovation and Paul Bonanos’ take on Monday’s $3.2 billion M&A move by Eli Lilly and Co. (NYSE:LLY).

This episode of BioCentury This Week was sponsored by Nxera Pharma Co. Ltd. For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.